Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Program Cuts Loom If ‘Cures’ Bill Isn’t Fully Funded, Ostroff Warns

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s acting commissioner says agency may have to ‘stop doing something else’ in order to cover the new responsibilities envisioned in the Cures legislation.


Related Content

Califf Sets Exit At FDA, Ostroff Could Return To Acting Commissioner Post
US FDA Might Be Temporarily Headed By Ostroff As Califf Sets His Departure
Senator Tells FDA To Create ‘Red Team’ For Regulatory Streamlining
FDA Staying The Course Under Ostroff; Hamburg’s Concerns Will Remain Focus





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts